Sign In
3 Nov 2015 15:15
ο»Ώ
Ap19
Β
Β
FORMΒ 8.3
Β
IRISHΒ TAKEOVERΒ PANEL
Β
DISCLOSUREΒ UNDERΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013
Β
DEALINGSΒ BYΒ PERSONSΒ WITHΒ INTERESTSΒ INΒ RELEVANTΒ SECURITIESΒ REPRESENTINGΒ 1%Β ORΒ MORE
Β
1. KEYΒ INFORMATION
Β
Name of person dealing (Note 1) | BlackRock, Inc. |
Company dealt in | Pfizer, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | US$0.05 common stock |
Date of dealing | 02 November 2015 |
Β
2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS
Β
(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)
Long | Short | |||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | 396,073,794 (6.41%) | 205,883 (0.00%) | ||||
(2) Derivatives (other than options) | 138,700 (0.00%) | 10,860 (0.00%) | ||||
(3) Options and agreements to purchase/sell | 20,000,000 (0.32%) | 21,477,400 (0.34%) | ||||
Total | 416,212,494 (6.74%) | 21,694,143 (0.35%) | ||||
Β
(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 3)
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
Β (2) Derivatives (other than options) | ||||||
Β (3) Options and agreements to purchase/sell | ||||||
Total | ||||||
Ap20
Β
Β
1. DEALINGSΒ (NoteΒ 4)
Β
(a) PurchasesΒ andΒ sales
Β
Β
Β Purchase/sale | Β Number of relevant securities | Β Price per unit (Note 5) |
Purchase | 36,700 | USD 33.8200 |
Purchase | 87,303 | USD 34.7223 |
Purchase | 10,000 | USD 34.8090 |
Purchase | 9,000 | USD 34.8632 |
Purchase | 32,402 | USD 35.0600 |
Sale | 94,900 | USD 33.8200 |
Sale | 172,920 | USD 34.9559 |
Sale | 701,622 | USD 35.0063 |
Sale | 441,080 | USD 35.0185 |
Sale | 8,526 | USD 35.0600 |
Sale | 32,500 | USD 35.0675 |
Sale | 21,030 | USD 35.0707 |
Please note: there was also a Transfer In of 210,193 Shares.
Β
(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)
Β
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities
Β
Β
(i) Writing,Β selling,Β purchasingΒ orΒ varying
Β
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
Call Option | Writing | 20,200 | USD 35.0000 | American | 11/12/2015 | USD 0.9500 |
Β
(ii) Exercising
Β
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
Β
(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)
Β
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
Ap21
Β
2. OTHERΒ INFORMATION
Β
Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives
Β
Β
FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β this shouldΒ beΒ stated.
Β
Β
Β
None
Β
Β
Β
IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) YES
Β
Date of disclosure | 03 November 2015 |
Contact name | Gareth Slade |
Telephone number | +44 20 7743 2536 |
If a connected EFM, name of offeree/offeror with which connected | |
If a connected EFM, state nature of connection (Note 10) |
Β
Β
Ap23
Β
Β
SUPPLEMENTAL FORM 8
Β
IRISH TAKEOVER PANEL
Β
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
Β
DETAILS OF OPEN POSITIONS
Β
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
Β
OPENΒ POSITIONSΒ (NoteΒ 1)
Β
Product name, e.g. call option | Written, or purchased | Number of relevant securities to which the option or derivative relates | Exercise price (Note 2) | Type, e.g. American, European etc. | Expiry date |
Call Option | Written | 273,100 | USD 35.0000 | American | 06/11/2015 |
Call Option | Written | 268,100 | USD 34.5000 | American | 13/11/2015 |
Call Option | Written | 261,300 | USD 34.0000 | American | 20/11/2015 |
Call Option | Written | 186,000 | USD 34.5000 | American | 20/11/2015 |
Call Option | Written | 3,500 | USD 35.0000 | American | 20/11/2015 |
Call Option | Written | 186,000 | USD 34.5000 | American | 04/12/2015 |
Call Option | Purchased | 20,000,000 | USD 34.5000 | American | 04/12/2015 |
Call Option | Written | 299,400 | USD 35.0000 | American | 11/12/2015 |
Call Option | Written | 20,000,000 | USD 37.5000 | American | 15/01/2016 |
Β
Notes
Β
1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivative positionsΒ (exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.Β FullΒ detailsΒ ofΒ anyΒ existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ must alsoΒ beΒ givenΒ onΒ thisΒ form.
Β
2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ must beΒ stated.
Β
ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RuleΒ 8Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.
Β
Follow the stocks
